The systemic nature of chronic lung disease

Clinics in Chest Medicine

Volumn 35, Issue 2, 2014, Pages 283-293

  Evans, Rachael A ^a   Morgan, Michael D L ^a  

^a GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Comorbidity; Dyspnea; Exercise; Pulmonary rehabilitation; Systemic manifestations

Indexed keywords

CORTICOSTEROID;

ANEMIA; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DYSLIPIDEMIA; DYSPNEA; ENDOCRINE DISEASE; HEALTH PROGRAM; HEART DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; HYPOXIA; INFLAMMATION; METABOLIC SYNDROME X; MOOD DISORDER; MYOPATHY; OBESITY; OSTEOPOROSIS; PHYSICAL INACTIVITY; PRIORITY JOURNAL; PULMONARY REHABILITATION; REVIEW;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; COMORBIDITY; DYSPNEA; EXERCISE; PULMONARY REHABILITATION; SYSTEMIC MANIFESTATIONS;

HUMANS; INFLAMMATION; METABOLIC SYNDROME X; MUSCULAR DISEASES; OSTEOPOROSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84901625166     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2014.02.009     Document Type: Review

References (110)

1. O'Donnell D.E., Revill S.M., Webb K.A. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164(5):770-777.
2. Evans R.A., Singh S.J., Collier R., et al. Pulmonary rehabilitation is successful for COPD irrespective of MRC dyspnoea grade. Respir Med 2009, 103(7):1070-1075.
3. Cockcroft A.E., Saunders M.J., Berry G. Randomised controlled trial of rehabilitation in chronic respiratory disability. Thorax 1981, 36(3):200-203.
4. McGavin C.R., Gupta S.P., Lloyd E.L., et al. Physical rehabilitation for the chronic bronchitic: results of a controlled trial of exercises in the home. Thorax 1977, 32(3):307-311.
5. Goldstein R.S., Gort E.H., Stubbing D., et al. Randomised controlled trial of respiratory rehabilitation. Lancet 1994, 344(8934):1394-1397.
6. Seymour J.M., Spruit M.A., Hopkinson N.S., et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 2010, 36(1):81-88.
7. Crisafulli E., Costi S., Luppi F., et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008, 63(6):487-492.
8. Hamilton A.L., Killian K.J., Summers E., et al. Symptom intensity and subjective limitation to exercise in patients with cardiorespiratory disorders. Chest 1996, 110(5):1255-1263.
9. Debigare R., Cote C.H., Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms. Am J Respir Crit Care Med 2001, 164(9):1712-1717.
10. Swallow E.B., Reyes D., Hopkinson N.S., et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 2007, 62(2):115-120.
11. Marquis K., Debigare R., Lacasse Y., et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166(6):809-813.
12. Decramer M., Gosselink R., Troosters T., et al. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997, 10(2):417-423.
13. Maltais F., Sullivan M.J., LeBlanc P., et al. Altered expression of myosin heavy chain in the vastus lateralis muscle in patients with COPD. Eur Respir J 1999, 13(4):850-854.
14. Whittom F., Jobin J., Simard P.M., et al. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc 1998, 30(10):1467-1474.
15. Maltais F., Simard A.A., Simard C., et al. Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am J Respir Crit Care Med 1996, 153(1):288-293.
16. Gosker H.R., Hesselink M.K., Duimel H., et al. Reduced mitochondrial density in the vastus lateralis muscle of patients with COPD. Eur Respir J 2007, 30(1):73-79.
17. Casaburi R., Patessio A., Ioli F., et al. Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. Am Rev Respir Dis 1991, 143(1):9-18.
18. Steiner M.C., Evans R., Deacon S.J., et al. Adenine nucleotide loss in the skeletal muscles during exercise in chronic obstructive pulmonary disease. Thorax 2005, 60(11):932-936.
19. Saey D., Debigare R., LeBlanc P., et al. Contractile leg fatigue after cycle exercise: a factor limiting exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 168(4):425-430.
20. Man W.D., Soliman M.G., Gearing J., et al. Symptoms and quadriceps fatigability after walking and cycling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 168(5):562-567.
21. Gagnon P., Saey D., Vivodtzev I., et al. Impact of pre-induced quadriceps fatigue on exercise response in chronic obstructive pulmonary disease and healthy subjects. JAppl Physiol (1985) 2009, 107(3):832-840.
22. Bolton C.E., Bevan-Smith E.F., Blakey J.D., et al. British Thoracic Society guideline on pulmonary rehabilitation in adults. Thorax 2013, 68(Suppl 2):ii1-ii30.
23. Spruit M.A., Singh S.J., Garvey C., et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013, 188(8):e13-e64.
24. Pitta F., Troosters T., Spruit M.A., et al. Activity monitoring for assessment of physical activities in daily life in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil 2005, 86(10):1979-1985.
25. Rochester D.F. The respiratory muscles in COPD. State of the art. Chest 1984, 85(Suppl 6):47S-50S.
26. Man W.D., Soliman M.G., Nikoletou D., et al. Non-volitional assessment of skeletal muscle strength in patients with chronic obstructive pulmonary disease. Thorax 2003, 58(8):665-669.
27. Levine S., Kaiser L., Leferovich J., et al. Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. NEngl J Med 1997, 337(25):1799-1806.
28. Polkey M.I., Kyroussis D., Keilty S.E., et al. Exhaustive treadmill exercise does not reduce twitch transdiaphragmatic pressure in patients with COPD. Am J Respir Crit Care Med 1995, 152(3):959-964.
29. Polkey M.I., Kyroussis D., Hamnegard C.H., et al. Diaphragm performance during maximal voluntary ventilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997, 155(2):642-648.
30. Mador M.J., Kufel T.J., Pineda L.A., et al. Diaphragmatic fatigue and high-intensity exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161(1):118-123.
31. Hill K., Geist R., Goldstein R.S., et al. Anxiety and depression in end-stage COPD. Eur Respir J 2008, 31(3):667-677.
32. Harrison S.L., Greening N.J., Williams J.E., et al. Have we underestimated the efficacy of pulmonary rehabilitation in improving mood?. Respir Med 2012, 106(6):838-844.
33. Debigare R., Marquis K., Cote C.H., et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003, 124(1):83-89.
34. Atlantis E., Fahey P., Cochrane B., et al. Endogenous testosterone level and testosterone supplementation therapy in chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open 2013, 3(8). pii:e003127.
35. Burdet L., de Muralt B., Schutz Y., et al. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study. Am J Respir Crit Care Med 1997, 156(6):1800-1806.
36. Graat-Verboom L., Wouters E.F., Smeenk F.W., et al. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J 2009, 34(1):209-218.
37. Biskobing D.M. COPD and osteoporosis. Chest 2002, 121(2):609-620.
38. Graat-Verboom L., Spruit M.A., van den Borne B.E., et al. Whole-body versus local dxa-scan for the diagnosis of osteoporosis in COPD patients. JOsteoporos 2010, 2010:640878.
39. Cote C., Zilberberg M.D., Mody S.H., et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 2007, 29(5):923-929.
40. Shorr A.F., Doyle J., Stern L., et al. Anemia in chronic obstructive pulmonary disease: epidemiology and economic implications. Curr Med Res Opin 2008, 24(4):1123-1130.
41. Booth F.W., Gollnick P.D. Effects of disuse on the structure and function of skeletal muscle. Med Sci Sports Exerc 1983, 15(5):415-420.
42. Pitta F., Troosters T., Spruit M.A., et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 171(9):972-977.
43. Serres I., Gautier V., Varray A., et al. Impaired skeletal muscle endurance related to physical inactivity and altered lung function in COPD patients. Chest 1998, 113(4):900-905.
44. Man W.D., Hopkinson N.S., Harraf F., et al. Abdominal muscle and quadriceps strength in chronic obstructive pulmonary disease. Thorax 2005, 60(9):718-722.
45. Schols A.M., Buurman W.A., Staal van den Brekel A.J., et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996, 51(8):819-824.
46. Broekhuizen R., Wouters E.F., Creutzberg E.C., et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006, 61(1):17-22.
47. Celli B.R., Locantore N., Yates J., et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185(10):1065-1072.
48. Lee J., Sandford A., Man P., et al. Is the aging process accelerated in chronic obstructive pulmonary disease?. Curr Opin Pulm Med 2011, 17(2):90-97.
49. Savale L., Chaouat A., Bastuji-Garin S., et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 179(7):566-571.
50. Montes de Oca M., Torres S.H., De Sanctis J., et al. Skeletal muscle inflammation and nitric oxide in patients with COPD. Eur Respir J 2005, 26(3):390-397.
51. Rabinovich R.A., Figueras M., Ardite E., et al. Increased tumour necrosis factor-alpha plasma levels during moderate-intensity exercise in COPD patients. Eur Respir J 2003, 21(5):789-794.
52. Petersen A.M., Penkowa M., Iversen M., et al. Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease. Lung 2007, 185(3):161-171.
53. Barreiro E., Schols A.M., Polkey M.I., et al. Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax 2008, 63(2):100-107.
54. John M., Lange A., Hoernig S., et al. Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases. Int J Cardiol 2006, 111(3):365-370.
55. Rutten E.P., Franssen F.M., Spruit M.A., et al. Anemia is associated with bone mineral density in chronic obstructive pulmonary disease. COPD 2013, 10(3):286-292.
56. Miller J., Edwards L.D., Agusti A., et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013, 107(9):1376-1384.
57. Sabit R., Bolton C.E., Edwards P.H., et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175(12):1259-1265.
58. Vanfleteren L.E., Spruit M.A., Groenen M., et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 187(7):728-735.
59. Howald H., Hoppeler H. Performing at extreme altitude: muscle cellular and subcellular adaptations. Eur J Appl Physiol 2003, 90(3-4):360-364.
60. MacDougall J.D., Green H.J., Sutton J.R., et al. Operation Everest II: structural adaptations in skeletal muscle in response to extreme simulated altitude. Acta Physiol Scand 1991, 142(3):421-427.
61. Jakobsson P., Jorfeldt L., Brundin A. Skeletal muscle metabolites and fibre types in patients with advanced chronic obstructive pulmonary disease (COPD), with and without chronic respiratory failure. Eur Respir J 1990, 3(2):192-196.
62. Pouw E.M., Koerts-de Lang E., Gosker H.R., et al. Muscle metabolic status in patients with severe COPD with and without long-term prednisolone. Eur Respir J 2000, 16(2):247-252.
63. Man W.D., Kemp P., Moxham J., et al. Exercise and muscle dysfunction in COPD: implications for pulmonary rehabilitation. Clin Sci (Lond) 2009, 117(8):281-291.
64. Kmietowicz Z. NICE publishes osteoporosis guidance after more than six years of consultation. BMJ 2008, 337:a2397.
65. Crisafulli E., Gorgone P., Vagaggini B., et al. Efficacy of standard rehabilitation in COPD outpatients with comorbidities. Eur Respir J 2010, 36(5):1042-1048.
66. Casaburi R., Bhasin S., Cosentino L., et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 170(8):870-878.
67. Steiner M.C., Barton R.L., Singh S.J., et al. Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease: a randomised controlled trial. Thorax 2003, 58(9):745-751.
68. Deacon S.J., Vincent E.E., Greenhaff P.L., et al. Randomized controlled trial of dietary creatine as an adjunct therapy to physical training in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 178(3):233-239.
69. Hawkins N.M., Jhund P.S., Simpson C.R., et al. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail 2010, 12(1):17-24.
70. Rutten F.H., Moons K.G., Cramer M.J., et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ 2005, 331(7529):1379.
71. Mascarenhas J., Lourenco P., Lopes R., et al. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J 2008, 155(3):521-525.
72. Macchia A., Rodriguez Moncalvo J.J., Kleinert M., et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J 2012, 39(1):51-58.
73. Curkendall S.M., DeLuise C., Jones J.K., et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006, 16(1):63-70.
74. Lavie C.J., Milani R.V., Verma A., et al. C-reactive protein and cardiovascular diseases-is it ready for primetime?. Am J Med Sci 2009, 338(6):486-492.
75. Willerson J.T. Systemic and local inflammation in patients with unstable atherosclerotic plaques. Prog Cardiovasc Dis 2002, 44(6):469-478.
76. Wisniacki N., Taylor W., Lye M., et al. Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart 2005, 91(1):32-37.
77. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 2005, 95(11A):3C-8C.
78. Garcia-Rio F., Miravitlles M., Soriano J.B., et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010, 11(1):63.
79. Higashimoto Y., Iwata T., Okada M., et al. Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med 2009, 103(8):1231-1238.
80. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. NEngl J Med 2007, 356(8):775-789.
81. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? the potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107(11):1514-1519.
82. Hole D.J., Watt G.C., Davey-Smith G., et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996, 313(7059):711-715.
83. Sin D.D., Man S.F. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005, 2(1):8-11.
84. Boudestein L.C., Rutten F.H., Cramer M.J., et al. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail 2009, 11(12):1182-1188.
85. De Blois J., Simard S., Atar D., et al. COPD predicts mortality in HF: the Norwegian Heart Failure Registry. JCard Fail 2010, 16(3):225-229.
86. Macchia A., Monte S., Romero M., et al. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur J Heart Fail 2007, 9(9):942-948.
87. Dunlay S.M., Redfield M.M., Weston S.A., et al. Hospitalizations after heart failure diagnosis a community perspective. JAm Coll Cardiol 2009, 54(18):1695-1702.
88. Staszewsky L., Wong M., Masson S., et al. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. JCard Fail 2007, 13(10):797-804.
89. Sirak T.E., Jelic S., Le Jemtel T.H. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. JAm Coll Cardiol 2004, 44(3):497-502.
90. Mentz R.J., Schulte P.J., Fleg J.L., et al. Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION). Am Heart J 2013, 165(2):193-199.
91. O'Connor C.M., Whellan D.J., Lee K.L., et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009, 301(14):1439-1450.
92. Gale N.S., Duckers J.M., Enright S., et al. Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD?. BMC Pulm Med 2011, 11:20.
93. Vivodtzev I., Minet C., Wuyam B., et al. Significant improvement in arterial stiffness after endurance training in patients with COPD. Chest 2010, 137(3):585-592.
94. Greening N.J., Evans R.A., Williams J.E., et al. Does body mass index influence the outcomes of a Waking-based pulmonary rehabilitation programme in COPD?. Chron Respir Dis 2012, 9(2):99-106.
95. Celli B.R., Thomas N.E., Anderson J.A., et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008, 178(4):332-338.
96. Padwal R.S., Pajewski N.M., Allison D.B., et al. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ 2011, 183(14):E1059-E1066.
97. Cao C., Wang R., Wang J., et al. Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS One 2012, 7(8):e43892.
98. Sava F., Laviolette L., Bernard S., et al. The impact of obesity on walking and cycling performance and response to pulmonary rehabilitation in COPD. BMC Pulm Med 2010, 10:55.
99. Ora J., Laveneziana P., Ofir D., et al. Combined effects of obesity and chronic obstructive pulmonary disease on dyspnea and exercise tolerance. Am J Respir Crit Care Med 2009, 180(10):964-971.
100. Watz H., Waschki B., Kirsten A., et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009, 136(4):1039-1046.
101. Lam K.B., Jordan R.E., Jiang C.Q., et al. Airflow obstruction and metabolic syndrome: the Guangzhou Biobank Cohort Study. Eur Respir J 2010, 35(2):317-323.
102. van den B.B., Gosker H.R., Zeegers M.P., et al. Pulmonary function in diabetes: a meta-analysis. Chest 2010, 138(2):393-406.
103. Walter R.E., Beiser A., Givelber R.J., et al. Association between glycemic state and lung function: the Framingham Heart Study. Am J Respir Crit Care Med 2003, 167(6):911-916.
104. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEngl J Med 2002, 346(6):393-403.
105. Wedzicha J.A., Bestall J.C., Garrod R., et al. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J 1998, 12(2):363-369.
106. Dolmage T.E., Goldstein R.S. Effects of one-legged exercise training of patients with COPD. Chest 2008, 133(2):370-376.
107. Bjorgen S., Hoff J., Husby V.S., et al. Aerobic high intensity one and two legs interval cycling in chronic obstructive pulmonary disease: the sum of the parts is greater than the whole. Eur J Appl Physiol 2009, 106(4):501-507.
108. Klijn P., van Keimpema A., Legemaat M., et al. Nonlinear exercise training in advanced chronic obstructive pulmonary disease is superior to traditional exercise training. A randomized trial. Am J Respir Crit Care Med 2013, 188(2):193-200.
109. Maddocks M., Gao W., Higginson I.J., et al. Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease. Cochrane Database Syst Rev 2013, (1). CD009419.
110. Johnson-Warrington V., Williams J., Bankart J., et al. Pulmonary rehabilitation and interstitial lung disease: aiding the referral decision. JCardiopulm Rehabil Prev 2013, 33(3):189-195.